29 completed, 16 recruiting, 14 unknown, 5 terminated. 74 Phase 1, 24 Phase 2.
Follow Advanced Breast Cancer: new trials by email Literature Review of Advanced Breast Cancer trials Research Report on Advanced Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors PF-08165784, Fulvestrant, Atirmociclib - Advanced Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 1 | Not yet recruiting | Pfizer | 268 | 2026-11-09 | 2026-10-28 |
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer ZOLADEX - Advanced Breast Cancer, Early Breast Cancer | Phase 1 | Recruiting | TerSera Therapeutics LLC | 176 | 2026-10-30 | 2026-10-13 |
| A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors [68Ga]Ga-DWJ155 - Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer | Phase 1 | Recruiting | Novartis Pharmaceuticals | 66 | 2026-09-08 | 2026-10-13 |
| Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors RGT-490 - Breast Cancer, Ovarian Cancer | Phase 1 | Recruiting | Regor Pharmaceuticals Inc. | 63 | 2026-06-01 | 2026-07-22 |
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer BBI-940, Fulvestrant - Breast Cancer, Metastatic Breast Cancer | Phase 1 | Terminated | Boundless Bio, Inc. | 8 | 2026-02-25 | 2026-08-19 |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) | Phase 1 | Recruiting | Pfizer | 260 | 2025-12-23 | 2026-07-22 |
| A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer QLC1401 - Advanced Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 96 | 2025-09-01 | 2025-09-15 |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors BMS-986500, Palbociclib, Fulvestrant - Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Recruiting | Bristol-Myers Squibb | 234 | 2025-08-01 | 2026-10-06 |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant - Advanced Solid Tumors, Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Ensem Therapeutics | 233 | 2025-06-10 | 2026-10-13 |
| HS-10502 Combination Treatment in Patients With Advanced Solid Tumors HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib - Recurrent Ovarian Cancer, HER2-negative | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 157 | 2025-05-07 | 2025-06-24 |
| A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer Sirolimus (albumin - bound), Palbociclib tablet, Fulvestrant injection - Advanced Breast Cancer | Phase 1 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 382 | 2025-04-30 | 2025-04-23 |
| Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer SHR-A1811, Ritonavir, Itraconazole - Advanced Breast Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 17 | 2025-02-17 | 2026-06-04 |
| Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer Debio 0123 and Sacituzumab govitecan - Advanced Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | MedSIR | 76 | 2025-01-17 | 2025-12-05 |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors BBO-10203, Trastuzumab, Fulvestrant - Solid Tumor, Adult, Metastatic Breast Cancer | Phase 1 | Recruiting | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 392 | 2024-10-29 | 2026-10-01 |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer MEN2312, Elacestrant - Advanced Breast Cancer | Phase 1 | Recruiting | Stemline Therapeutics, Inc. | 240 | 2024-10-25 | 2026-08-07 |
| Study of DM5167 in Patients With Advanced Solid Tumors DM5167 - Advanced Breast Cancer | Phase 1 | Recruiting | DIGMBIO | 58 | 2024-10-24 | 2025-08-03 |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. RYZ101, Standard of Care Endocrine Therapy - Metastatic Breast Cancer, HER2-negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | RayzeBio, Inc. | 64 | 2024-07-19 | 2026-10-06 |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd Patritumab deruxtecan, Olaparib - Breast Cancer Metastatic, HER2-positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 152 | 2024-03-21 | 2026-09-04 |
| Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T) XKDCT293, CAR-T cell - Advanced Breast Cancer | Phase 1 | Unknown | Shenzhen Celconta Life Science Co., Ltd. | 18 | 2024-03-11 | 2024-12-09 |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer Hydroxychloroquine, Sacituzumab Govitecan, Trastuzumab Deruxtecan - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 120 | 2024-01-29 | 2024-03-25 |
Showing 20 of 74. Sign in to see all of them.
Breast Neoplasms (31) · Endometrial Neoplasms (5) · Neoplasms (5) · Ovarian Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Prostatic Neoplasms (3) · Colonic Neoplasms (2) · Fallopian Tube Neoplasms (2) · Neoplasm Metastasis (2) · Stomach Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1)
Neoplasms by Site (33) · Neoplasms (31) · Skin Diseases (31) · Skin and Connective Tissue Diseases (31) · Breast Diseases (30) · Genital Diseases (9) · Neoplasms by Histologic Type (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7)
Fulvestrant (18) · palbociclib (9) · Letrozole (8) · ribociclib (4) · Bevacizumab (3) · Paclitaxel (3) · Trastuzumab (3) · abemaciclib (3) · Albumin-Bound Paclitaxel (2) · Anastrozole (2) · Cetuximab (2) · Docetaxel (2) · Hydroxychloroquine (2) · elacestrant (2) · neratinib (2)
Pfizer (4) · Abramson Cancer Center at Penn Medicine (2) · Bristol-Myers Squibb (2) · CSPC Ouyi Pharmaceutical Co., Ltd. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · MedSIR (2) · National Cancer Institute (NCI) (2) · Nuvation Bio Inc. (2) · Puma Biotechnology, Inc. (2) · Qilu Pharmaceutical Co., Ltd. (2) · Relay Therapeutics, Inc. (2) · Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Ahon Pharmaceutical Co., Ltd. (1)
United States (35) · China (25) · France (8) · Spain (8) · South Korea (7) · Japan (6) · Australia (5) · Belgium (3) · India (3) · Italy (3) · United Kingdom (3) · Brazil (2) · Canada (2) · Denmark (2) · Moldova (2)
Adam Ostrowski, MD (1) · Alice P Chen, M.D. (1) · Amy Clark, MD (1) · Barbara Haley, MD (1) · Binhe Xu, MD (1) · Cheng Huang, MD (1) · Christine Fredericks (1) · Eric P. Hailman, MD, PhD (1)
PMID 21931708, PMID 22547604, PMID 23632474, PMID 27902470, PMID 28228842, PMID 28445973, PMID 28650446, PMID 29948356, PMID 30042390, PMID 30792217, PMID 30796032, PMID 31194225, PMID 31194228, PMID 32193378, PMID 33835229, PMID 34554584, PMID 35235412, PMID 35436589, PMID 38010394, PMID 38057772, PMID 38940019, PMID 39188943, PMID 39229468, PMID 39241211, PMID 39746964, PMID 40013319, PMID 41063198, PMID 41423595
2023 (2), 2025 (2), 2017 (1), 2019 (1)